Table 2.
Registered clinical trials with extracellular vesicles in ClinicalTrials.gov
| Identifier | Last update | Phase of clinical trial | Condition or disease | Source of EVs | Intervention/treatment | Recruitment status |
|---|---|---|---|---|---|---|
| NCT05243368 | February 17, 2022 | phase 1 | foot, diabetic chronic skin ulcers | mesenchymal stem cells | Dietary supplement: personalized nutritional intervention. Those with malnutrition criteria will also receive a nutritional supplement. The aim will be to provide at least 50% of the recommended intakes for the main nutrients related to wound healing. |
not yet recruiting |
| NCT04134676 | June 22, 2020 | phase 1 | chronic ulcer | Wharton’s jelly mesenchymal stem cells | Drug: conditioned media. These components may be capable of initiating regeneration and repair on their own, as well as mediating the ex vivo de novo organogenesis of tissue-engineered organs. |
completed |
| NCT02565264 | September 9, 2020 | early phase 1 | Ulcer | plasma-derived exosomes | The plasma-derived exosomes will be administered to the ulcers of the participants on a regular basis for 28 days. | unknown |
| NCT04652531 | December 7, 2020 | early phase 1 | Ulcer Venous | autologous extracellular vesicles from serum | The vesicles will be injected into the wound in a sterile environment. An elastic compression bandage and sterile gauze will be used. | recruiting |
| NCT04281901 | August 3, 2021 | phase 1 | Otitis Media Chronic Temporal Bone | platelet- and extracellular vesicle-rich plasma | Platelet- and extracellular vesicle-rich plasma: ear wick immersed in platelet- and extracellular vesicle-rich plasma | completed |
| NCT05078385 | October 14, 2021 | phase 1 | Burns | bone marrow-derived mesenchymal stem cells | Drug: AGLE-102. Many of the therapeutic effects induced by MSCs are mediated by EVs derived from MSCs, which may be a safer, more reliable option to allogeneic cell treatment. |
not yet recruiting |
MSC, mesenchymal stromal cell; AGLE, Aegle Therapeutics.